| Higher Ground Services Llc | |
|
235 Center St Brewer ME 04412-1961 | |
| (207) 299-5157 | |
| Not Available |
| Full Name | Higher Ground Services Llc |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 235 Center St, Brewer, Maine |
| Authorized Official Name and Position | James Michael Lapierre (CLINICAL DIRECTOR) |
| Authorized Official Contact | 2072995157 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Higher Ground Services Llc 235 Center St Brewer ME 04412-1961 Ph: (207) 299-5157 | Higher Ground Services Llc 235 Center St Brewer ME 04412-1961 Ph: (207) 299-5157 |
| NPI Number | 1265767446 |
|---|---|
| Provider Enumeration Date | 10/06/2009 |
| Last Update Date | 01/06/2010 |
| Medicare PECOS PAC ID | 0345381836 |
|---|---|
| Medicare Enrollment ID | O20100106000215 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265767446 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | 594362 (Maine) | Primary |
| 251S00000X | Community/behavioral Health | 594372 (Maine) | Secondary |
| Provider Name | James M Lapierre |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1265432959 PECOS PAC ID: 4183670409 Enrollment ID: I20050329001135 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Daniel James Robbins |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1538592787 PECOS PAC ID: 0840547725 Enrollment ID: I20180724001095 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Chelsea Rose Mucciarone |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1407245632 PECOS PAC ID: 0244589133 Enrollment ID: I20180827001688 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Justin J Umel |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1821446485 PECOS PAC ID: 4587992524 Enrollment ID: I20190828003488 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Kelly Denise Mclaughlin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1568587533 PECOS PAC ID: 1456745322 Enrollment ID: I20220219000095 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Michael Paul Gingras |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1316470784 PECOS PAC ID: 5496107302 Enrollment ID: I20240116004285 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Debra J Mcintyre |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1992211338 PECOS PAC ID: 6305298076 Enrollment ID: I20240118000622 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
| Provider Name | Garrett Boardway |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1215523717 PECOS PAC ID: 3577906031 Enrollment ID: I20240212002836 |
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
News Archive
A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.
On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.
Children and adolescents with an injury or disability may use mobility aids such as crutches, walkers and wheelchairs to help them move around more easily. However, use of these aids has been associated with risk for injury.
Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
› Verified 6 days ago
Root & Rise Psychotherapy, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 191 S Main St Ste 5, Brewer, ME 04412 Phone: 207-307-7704 Fax: 207-573-1108 | |
Bhs For Me, Llp Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 16 Craig Dr, Brewer, ME 04412 Phone: 207-991-3920 | |
Holistic Psychiatry Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 12 Acme Rd Ste 102, Brewer, ME 04412 Phone: 207-299-1997 Fax: 207-387-2828 | |
Hearts-ease Mental Health, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 451 S Main St, Brewer, ME 04412 Phone: 207-217-6551 Fax: 207-217-6552 | |
Spooky Barbie Healing Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 12 Acme Rd Ste 207, Brewer, ME 04412 Phone: 207-356-7904 | |
Mckay Counseling Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 235 Center St, Brewer, ME 04412 Phone: 207-478-6536 |